NASDAQ:APOP

Cellect Biotechnology (APOP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$13.10
$13.37
50-Day Range
$7.54
$13.40
52-Week Range
$6.64
$35.52
Volume
17,400 shs
Average Volume
479,845 shs
Market Capitalization
$12.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
APOP stock logo

About Cellect Biotechnology Stock (NASDAQ:APOP)

Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.

APOP Stock News Headlines

Krystal Biotech Inc.
Raleigh/Durham Biotech News
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Why These Biotech Stocks Are Outperforming the Market
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Seeing Good Action in Biotechnology Stocks
Why Cellect Biotechnology Shares Are Rising Today
Pre-market Movers: APOP, FBRX, ANY, AGIL, ADXS…
See More Headlines
Receive APOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellect Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2018
Today
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:APOP
Employees
2,020
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.77 per share

Miscellaneous

Free Float
N/A
Market Cap
$12.87 million
Optionable
Not Optionable
Beta
1.87
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Shai Yarkoni
    Chief Executive Officer & Director
  • Amos Ofer
    Chief Operating Officer
  • Yaron Ben-Oz
    Chief Financial Officer

APOP Stock Analysis - Frequently Asked Questions

How were Cellect Biotechnology's earnings last quarter?

Cellect Biotechnology Ltd. (NASDAQ:APOP) issued its earnings results on Tuesday, November, 13th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.02.

When did Cellect Biotechnology's stock split?

Cellect Biotechnology shares split before market open on Tuesday, October 26th 2021. The 2-1 split was announced on Tuesday, October 26th 2021. The newly minted shares were issued to shareholders after the closing bell on Tuesday, October 26th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What other stocks do shareholders of Cellect Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellect Biotechnology investors own include Elbit Systems (ESLT), Gilead Sciences (GILD), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Acasti Pharma (ACST), Allergan (AGN), Novavax (NVAX) and RedHill Biopharma (RDHL).

This page (NASDAQ:APOP) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners